Alaunos Therapeutics, Inc. (TCRT) resolved a delisting threat after Nasdaq confirmed the company regained compliance with its stockholders' equity requirement. The development eliminates a scheduled hearing that would have determined the fate of the company's listing on The Nasdaq Capital Market.
The issue originated on April 9, 2026, when the Listing Qualifications Department of The Nasdaq Stock Market LLC notified Alaunos Therapeutics of non-compliance with Nasdaq Listing Rule 5550(b)(1). This rule requires companies on The Nasdaq Capital Market to maintain a minimum of $2,500,000 in stockholders' equity. On October 5, 2026, Nasdaq informed the company that its securities were subject to delisting unless it requested a hearing. Alaunos Therapeutics timely requested the hearing, which was initially set for November 10, 2026.
In a previous Form 8-K filed on October 21, 2026, the company stated it believed it had regained compliance following the completion of a private placement financing on October 14, 2026. The October 22 letter from Nasdaq's Office of General Counsel confirmed this belief. As a result, Nasdaq determined the matter is closed, cancelled the November 10 hearing, and confirmed that Alaunos Therapeutics common stock will continue to be listed and traded on The Nasdaq Capital Market.
The company noted that its continued listing is subject to forward-looking risks. These include the impact of operating losses and transaction costs on stockholders' equity and the possibility that preliminary accounting conclusions regarding preferred stock classification may change during the financial statement close process or audit. Additionally, the company must obtain stockholder approvals as contemplated in its October 13, 2026 filing. Alaunos Therapeutics faces delisting risk if it does not evidence compliance with other Nasdaq listing requirements when filing its Annual Report on Form 10-K for the fiscal year ending December 31, 2026. The company is headquartered in Fort Lauderdale, Florida, and its common stock trades under the ticker TCRT.